- Home
- ORGN vs CANF Comparison
ORGN vs CANF Comparison
Compare ORGN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORGN | CANF |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United States | Israel |
| Employees | 91 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.2M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | ORGN | CANF |
|---|---|---|
| Price | $1.49 | $3.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 1.2M | 940.8K |
| Earning Date | 05-14-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $503.74 | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.17 |
| 52 Week High | $4.11 | $10.40 |
Technical Indicators
Market Signals| Indicator | ORGN | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 51.36 |
| Support Level | $1.29 | $2.89 |
| Resistance Level | $2.64 | $4.74 |
| Average True Range (ATR) | 0.20 | 0.30 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 24.32 | 48.05 |
Price Performance
Historical ComparisonAbout ORGN Origin Materials Inc.
Origin Materials Inc is a technology company with a mission to enable the world's transition to sustainable materials. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include PET circular caps and closures, Para-xylene, carbon black, Levulinic acid, among others, by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.